Solid Biosciences Inc. (SLDB) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
the bull case· 4
8
disclosed supplier and customer ties reported in SEC filings
sec filingsedgar4
funds on file reporting a position in the company
n-portas of Jun 30 '26+23.20%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26156
managers reporting a position in thirteen f regulatory filings
13fJun 30 '26the bear case· 4
0.24%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '2617
managers whose positions together make up four fifths of the reported value
13fJun 30 '264 of 21
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '264 of 5
recent reports where the move came in under the options implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
High 8.91 at 3:45 pm ET, low 8.66 at 3:30 pm ET.
Solid Biosciences Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Of the 6 companies Solid Biosciences Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
156 managers report a position worth $1.1B between them, and 17 of them hold 80% of it.
tall tick = annual report · 1 on record
SLDB (Solid Biosciences Inc.) has 8 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.